A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma
Citations Over TimeTop 10% of 2015 papers
Abstract
Epidermal growth factor receptor (EGFR) signalling is a potent driver of glioblastoma, a malignant and lethal form of brain cancer. Disappointingly, inhibitors targeting receptor tyrosine kinase activity are not clinically effective and EGFR persists on the plasma membrane to maintain tumour growth and invasiveness. Here we show that endolysosomal pH is critical for receptor sorting and turnover. By functioning as a leak pathway for protons, the Na(+)/H(+) exchanger NHE9 limits luminal acidification to circumvent EGFR turnover and prolong downstream signalling pathways that drive tumour growth and migration. In glioblastoma, NHE9 expression is associated with stem/progenitor characteristics, radiochemoresistance, poor prognosis and invasive growth in vitro and in vivo. Silencing or inhibition of NHE9 in brain tumour-initiating cells attenuates tumoursphere formation and improves efficacy of EGFR inhibitor. Thus, NHE9 mediates inside-out control of oncogenic signalling and is a highly druggable target for pan-specific receptor clearance in cancer therapy.
Related Papers
- → Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma(2012)30 cited
- → Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report(2014)6 cited
- → In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor(2016)3 cited
- → Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)(2012)1 cited
- Blocking epidermal growth factor receptor signal pathway to inhibit cell growth of nasopharynx cancer(2009)